Patritumab Deruxtecan Demonstrates a Manageable Safety Profile and Durable Efficacy in Heavily Pretreated Patients with Advanced Breast Cancer
Findings from the U31402-A-J101 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1551 results
Stringently Defined Clinical Complete Response After Gemcitabine, Cisplatin, Plus Nivolumab Facilitates Bladder Sparing in Patients with Muscle-Invasive Bladder Cancer
Findings from the HCRN GU 16–257 study
EMA Recommends Extending the Indications for Dostarlimab
New indication concerns a combination treatment with carboplatin and paclitaxel for adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer
FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer with a BRAF V600E Mutation
It also approved the FoundationOne CDx (tissue) and FoundationOne Liquid CDx (plasma) as companion diagnostics
FDA Approves Bosutinib for Paediatric Patients with Chronic Myelogenous Leukaemia
Evidence for efficacy is based on the results from the BCHILD study
EMA Recommends Extending Indications for Trastuzumab Deruxtecan to Include Treatment of Advanced HER2-mutated NSCLC
It is intended for patients who require systemic treatment following platinum-based chemotherapy with or without immunotherapy
Efficacy of Dabrafenib Plus Trametinib in First-Line Treatment for Children and Adolescents with Low-Grade Glioma with BRAF V600 Mutations
Findings from the phase II study
A Combination of Amivantamab and Lazertinib Shows Durable Clinical Activity in the Osimertinib-Relapsed EGFR-mutated Advanced NSCLC Setting
Findings from the cohort E of CHRYSALIS study
A Combination of Tucatinib and Trastuzumab Demonstrates Activity and Favourable Tolerability in Patients with Previously Treated HER2-positive Metastatic Biliary Tract Cancer
Findings from the BTC cohort of SGNTUC-019 study
EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in NSCLC
It is intended as monotherapy for the adjuvant treatment of adults with non-small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy
Axicabtagene Ciloleucel Results in High Response Rates and Durable Remissions as a Second-Line Treatment for Patients with Relapsed or Refractory Large B Cell Lymphoma Ineligible for ASCT
Findings from the ALYCANTE study
An Alternative Model for Genetic Testing Delivery Proposed with Posttest Counselling for Those with Pathogenic Variants and On Demand for Those Without Pathogenic Variants
Findings from the MAGENTA study